Pfizer Inc. Chief Executive Hank McKinnell says the companys Bextra anti-inflammatory drug will probably return to the market because of patient demand, according to Reuters.

Last month, the Food and Drug Administration forced Manhattan-based Pfizer to suspend sales of the Cox-2 inhibitor drug because of concerns about its health risks, and said Celebrex, another Cox-2 inhibitor, should carry a black box warning the strongest possible caution.

Late last year, Pfizer put a black box warning on Bextra, citing cardiovascular risks, and the risk of a rare but fatal skin rash.

In an interview with Reuters today, following a speech at an HIV/AIDS prevention meeting in Atlanta, Mr. McKinnell said Bextra was the best choice or the only choice for some patients.

The company issued a statement, saying it plans to discuss options with the FDA under which Bextra might be made available to those patients.



We're here to help!

We live by our creed of “helping those who need it most” and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked * may be required for submission.


Beasley Allen Law Firm
What is Bextra? Bextra is valdecoxib-based drug that is administered orally. Bextra is used as treatment...

I never dreamed how much this would mean to me

I received another check today, much to my surprise. Thank you, thank you, thank you! I never dreamed how much this would mean to me in my golden years, as I have had hearing problems for years and needed to update my hearing aids, but with a limited income, found that was impossible. I now have the best hearing aids that I have ever had, thanks to you fighting so hard on my behalf.

—Gladys